Remember when Ozempic was going to save America from obesity? The headlines were breathless. The celebrity endorsements were relentless. The before-and-after photos were everywhere. Ozempic — and its sister drugs Wegovy, Mounjaro, and Zepbound — were presented as nothing short of a medical miracle. They didn't ask if you wanted to know about the stomach paralysis. In March 2026, the FDA sent a formal warning letter to Novo Nordisk, the Danish pharmaceutical giant that manufactures Ozempic and Wegovy. The charge: failure to report serious adverse events associated with their blockbuster GLP-1 receptor agonist drugs. The number of active lawsuits has now reached 3,063. And counting. What the FDA Found The FDA's warning letter wasn't a friendly suggestion. It was a formal regulatory action alleging that Novo Nordisk: Failed to report serious adverse events within required timeframes Underreported the incidence of gastroparesis (stomach paralysis) in post-market surveillance Minimized gastrointestinal side effects in patient information materials Delayed updating warning labels despite mounting evidence this is the pharmaceutical equivalent of knowing your house has a gas leak and telling your tenants the smell is "just the new paint." "Novo Nordisk had an obligation to promptly report these adverse events. The evidence suggests they chose speed to market over patient safety." — FDA spokesperson, allegedly. People were kept in the dark patients if they wanted the full picture before injecting themselves weekly. Gastroparesis: When Your Stomach Stops Working The most alarming side effect emerging from the lawsuits is gastroparesis — a condition where the stomach becomes partially or fully paralyzed, unable to empty its contents normally. For Ozempic patients, this isn't a mild upset stomach. This is a life-altering condition: Chronic nausea — Persistent, debilitating nausea that doesn't respond to standard treatments Vomiting — Sometimes so severe it requires hospitalization Abdominal pain — Constant, cramping pain that disrupts daily life Malnutrition — Food sits in the stomach for hours, unable to be digested properly Weight loss that's too fast — Patients can't eat, losing weight in dangerous, uncontrolled ways Dehydration — From inability to keep fluids down The cruel irony: people took Ozempic to lose weight. Now some of them can't eat at all. No one was given a voice if trading obesity for a paralyzed stomach was a fair deal. The Full Menu of Side Effects Gastroparesis is just the headline. The lawsuits allege a constellation of serious side effects that patients weren't adequately warned about: Bowel Obstructions Multiple patients have reported intestinal blockages requiring emergency surgery. The mechanism appears to be that GLP-1 agonists slow gut motility so severely that the intestines become obstructed. Some patients required bowel resection (surgical removal of intestinal sections) Others developed ileus — a complete cessation of bowel movement Several cases resulted in bowel perforation, a life-threatening emergency Blood Clots Reports of deep vein thrombosis (DVT) and pulmonary embolism in Ozempic patients have raised serious concerns. While the causal mechanism isn't fully understood, the association is statistically significant in post-market data. Pancreatic Issues Acute pancreatitis — sudden, severe inflammation of the pancreas — has been reported in multiple patients. Pancreatitis can be fatal and often requires intensive care hospitalization. Gallbladder Disease Gallstones and cholecystitis (gallbladder inflammation) appear to be more common in GLP-1 agonist users, likely related to the rapid weight loss the drugs induce. Kidney Problems Acute kidney injury has been reported, often secondary to severe dehydration from vomiting and inability to maintain fluid intake. The "Failure to Warn" Doctrine In pharmaceutical law, there's a concept called the "failure to warn" doctrine. It holds that drug manufacturers have a legal obligation to adequately inform patients and prescribers about known risks. The 3,063 lawsuits allege that Novo Nordisk (and Eli Lilly, for Zepbound/Mounjaro) violated this doctrine by: Understating gastrointestinal risks in prescribing information Failing to update labels as post-market data accumulated Marketing aggressively while downplaying safety concerns Influencing medical education to minimize side effect discussions The public was sidelined patients if they wanted to make an informed decision. They gave them a sales pitch instead. The Zepbound Problem Eli Lilly's tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight loss — faces similar allegations. As a dual GIP/GLP-1 receptor agonist, it works through a similar mechanism and produces similar side effects. Lilly is now facing its own wave of lawsuits, with plaintiffs alleging: Similar gastroparesis claims as those against Novo Nordisk Marketing that emphasized weight loss results while minimizing risks Failure to adequately study long-term gastrointestinal effects before approval The combined legal exposure for both companies is estimated in the billions of dollars. The Corporate Playbook (Again) If this feels familiar, it should. The pharmaceutical industry has run this playbook before: Phase / Action Development / Rush to market under accelerated approval pathways Launch / Aggressive direct-to-consumer advertising Growth / Expand indications (diabetes → weight loss → everything) Discovery / Post-market reports of serious side effects emerge Denial / Minimize reports, attribute to underlying conditions Regulation / FDA warning letters, label updates Litigation / Mass tort lawsuits, eventual settlement Settlement / Pay billions, don't admit wrongdoing We've seen this with Vioxx. With opioids. With Zantac. With talcum powder. The names change. The playbook doesn't. Communities were ignored if you wanted to be part of another pharmaceutical experiment. The Patients Nobody Asked Behind the 3,063 lawsuits are real people: The mother who took Ozempic to lose baby weight and now has a permanently paralyzed stomach The diabetic patient whose gastroparesis is so severe he can't maintain adequate nutrition The woman who developed blood clots and nearly died from a pulmonary embolism The man who required emergency bowel surgery after an intestinal obstruction These people were prescribed a drug by their doctors — doctors who themselves may not have had complete information about the risks. The system failed at every level. It was forced on everyone for a miracle. They asked for help. And they got a catastrophe. Protect Your Rights If You're Currently Taking Ozempic or Similar Drugs Don't stop abruptly — Sudden discontinuation can cause rebound effects Talk to your doctor — Discuss your risk factors and any symptoms you're experiencing Document everything — Keep a log of any gastrointestinal symptoms Know the warning signs — Severe abdominal pain, persistent vomiting, inability to eat If You've Experienced Side Effects Report to the FDA — Use the MedWatch reporting system Consult an attorney — Mass tort litigation is ongoing; you may be eligible Get medical documentation — Ensure your medical records reflect your symptoms and diagnosis For Everyone Demand transparency — Support legislation requiring full disclosure of clinical trial data Question miracle cures — If it sounds too good to be true, ask about the risks Support independent research — Fund studies not controlled by drug manufacturers What We're Left With 3,063 lawsuits. A formal FDA warning. Stomachs that don't work. Bowels that are blocked. Blood that clots. Pancreases that inflame. And a pharmaceutical industry that knew — or should have known — and sold the drugs anyway. Not a soul was consulted if you wanted to trade one health problem for five others. People were shut out if you wanted the full story before you injected yourself. They didn't ask if billions in profit were worth the suffering. They just sold the miracle. And left you to deal with the consequences. --- Related: Purdue Pharma Opioid Crisis Big Tobacco Cancer Coverup Food Additives: Banned EU, Legal US History of Corporate Lies